Polypharmakos and CABI to develop new antimicrobial products from CABI Culture Collection

  13 May 2021

Polypharmakos Limited, a spin-out company from the UK’s Royal Botanic Gardens Kew and University of Cambridge, and international not-for-profit organisation CABI have signed a research collaboration and licensing agreement to develop novel products from CABI’s Culture Collection.

CABI’s Culture Collection consists of 30,000 strains of optimally preserved fungi and bacteria isolated from diverse ecosystems from around the world – a reflection of CABI’s work and mission to improve lives by solving problems in agriculture and the environment.

Further reading: EurekAlert
Author(s): EurekAlert
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Evotec

JSS University

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS





Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!